The impact the atmospheric air dust fractions and toxic metals on external respiratory function among chronic obstructive pulmonary disease patients

3rd International Conference on Energy Engineering and Environmental Protection

能源学;生态环境科学

Veremchuk, Lyudmila Vasilevna^1 ; Mineeva, Elena Evgenevna^1 ; Vitkina, Tatyana Isaakovna^1 ; Sidletskaya, Karolina Andreevna^1

Vladivostok Branch of Federal State Budgetary Science Institution, Far Eastern Scientific Center of Physiology and Pathology of Respiration, Research Institute of Medical Climatology and Rehabilitative Treatment, Vladivostok, Russia^1

关键词: Atmospheric air;    Chronic obstructive pulmonary disease;    Individual risks;    Parameters characterizing;    Potential risks;    Respiratory function;    Suspended particulate matters;    Trigger factors;   

Others  :  https://iopscience.iop.org/article/10.1088/1755-1315/227/5/052012/pdf
DOI  :  10.1088/1755-1315/227/5/052012

学科分类：环境科学（综合）

来源: IOP

【 摘 要 】

The study is dedicated to the potential risk determination of external respiratory function (ERF) disorders among chronic obstructive pulmonary disease (COPD) patients under dust fractions and toxic metals influence in Vladivostok atmosphere. The risk assessment included the environmental ERF trigger factors identification among COPD patients by regression analysis, the number of patients responding to factor exposure determination and the analysis of the possible ERF disorders individual risk among COPD patients. It is found that Vladivostok air pollution by dust aerosols and toxic metals directly affects COPD patients' ERF. The most significant effect on the bronchial mucosa, aggravating bronchial patency (r=11.6%) and lung hyperinflation (r=10.7%) have ultrafine suspended particulate matter (SPM) fractions (0-1 μm). Fine SPM fractions (1-10 μm) affect ERF parameters characterizing bronchial patency only and less than ultrafine fractions (r=10.2%). Toxic metals (Ni, Zn) equally influence bronchial patency and lung tissue hyperinflation indicators among COPD patients (r=29.8% and r=29.1% respectively).